COG

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, September 9, 2021

ET) and one-on-one meetings

Key Points: 
  • ET) and one-on-one meetings
    For additional information, please visit the investor relations section of the Companys website at:
    Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric patients.
  • Unfortunately, platinum-based therapies cause ototoxicity, or hearing loss, which is permanent, irreversible and particularly harmful to the survivors of pediatric cancer.
  • Fennec disclaims any obligation to update these forward-looking statements except as required by law.
  • For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com .

PyroGenesis Closes Strategic Acquisition of Air Science Technologies

Retrieved on: 
Thursday, August 12, 2021
Time, 0 A.D. (video game), ISO 9001:2015, Corporation, Forward-looking statement, GHG, History, COVID, PRRS, COG, Certification, Probability, 3D, Nasdaq, Toronto Stock Exchange, Contract, Hydrogen, LLC, ISO, Research, Ownership, Waste management, Acquisition, Greenhouse, Growth, Iron, Aluminium, Technology, Electricity, Plasma, Methanol, FEM, CFD, AST, Ethanol, Solution, Risk management

Can you describe the advantage of this transaction for PyroGenesis shareholders?

Key Points: 
  • Can you describe the advantage of this transaction for PyroGenesis shareholders?
  • We believe PyroGenesis acquisition of AST will now allow AST, under PyroGenesis, to realize its full potential by providing the requisite skill set and assets to grow and meet future demand.
  • In discussions with clients during our due diligence, we confirmed that any existing issues were entirely manageable and there was clear interest to expand the relationship under PyroGenesis ownership.
  • In PyroGenesis case, the syngas is converted into electricity and heat which are both low value products.

Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 10, 2021
Germ cell tumor, Health, Fennec, Priority review, Instability, Ototoxicity, FDA, Patient, PDUFA, Survival, Patent, COVID-19, CRL, COG, Goal, Disease, Survivor, Neuroblastoma, Medulloblastoma, Kool-Aid, Coronavirus, Exchange, Human, Hearing loss, Hepatoblastoma, Incidence, U.S. Securities and Exchange Commission, Osteosarcoma, MAA, EMA, Forward-looking statement, Annual report, Cisplatin, Contagious disease, Risk, NDA, Company, Literacy, Science, Security (finance), Failure, Platinum, Cancer, OHSU, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKfor the prevention of platinum-induced ototoxicity in pediatric patients.
  • Fennec disclaims any obligation to update these forward-looking statements except as required by law.
  • For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com .